1 September 2011


Baker & McKenzie has advised Cellestis Limited in connection with the A$363 million acquisition of Cellestis by global technology company QIAGEN N.V. by way of scheme of arrangement.  The scheme of arrangement was implemented on 29 August 2011.


Cellestis Limited is an Australian biotechnology company which has developed and commercialised a leading test for diagnosing tuberculosis worldwide.  Cellestis operates in the United States, Japan, Europe and in Australia.


QIAGEN is a global provider of sample and assay technologies for research in molecular diagnostics, applied testing, pharmaceuticals and academic research.


Melbourne Corporate partner Simon De Young led the transaction, with the assistance of Disputes Resolution partner Alex Wolff and Corporate senior asociate Rick Troiano. The Baker & McKenzie team worked closely with Credit Suisse as financial adviser to Cellestis.


Commenting on the transaction, Baker & McKenzie partner, Simon De Young said, "Baker & McKenzie was delighted to assist Cellestis in implementing this significant transaction in the global diagnostics sector, further demonstrating Baker & McKenzie's expertise in the life sciences industry."


Freehills advised QIAGEN.

Leave a Reply

You must be logged in to post a comment.